| Literature DB >> 35617293 |
Leriana Garcia Reis1, Thiago Henrique da Silva1, Márcia Saladini Vieira Salles2, André Furugen Cesar Andrade3, Simone Maria Massami Kitamura Martins1, Paula Lumy Takeuchi4, Ana Maria Centola Vidal5, Arlindo Saran Netto1.
Abstract
The concern with human health has increased the interest in producing foods enriched with polyunsaturated fatty acids (PUFA), directly or naturally, by inclusion in the animals' diet. The positive effects such as antithrombotic, anti-inflammatory, and hypolipidemic have been observed in pigs and rats, used as human models for study. The present study evaluated the effect of cow's milk with different lipid profiles on performance, serum fatty acid profile, biochemical analysis, and a complete blood count of gilts used as a human model. At 34 days, thirty gilts were equally distributed in three treatments. Experimental treatments were milk from cows without the oil supplementation (C), milk from cows fed an enriched diet with linseed oil (n-3), and milk from cows fed an enriched diet with soybean oil (n-6). Milk supplementation was performed until 190 days old, provided once in the morning. The n-3 and n-6 milk reduced the concentration of myristic acid in the blood and increased the leukocytes. Milk enriched with n-3 compared to n-6 reduced the stearic acid. In conclusion, milk with a better PUFA profile can reduce saturated fatty acids in the blood and alter the concentration of cells in the defense system.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35617293 PMCID: PMC9135250 DOI: 10.1371/journal.pone.0258629
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Composition of pre-initial, initial, growth and termination diets, specific to each physiological phase of swine females.
| Item | Pre-initial | Initial | Grower | Finisher | Replacement | Gestation | Lactation |
|---|---|---|---|---|---|---|---|
| Ground corn | 399.0 | 649.0 | 699.0 | 739.0 | 644.4 | 594.0 | 587.8 |
| Soybean meal | 200.0 | 300.0 | 280.0 | 240.0 | 240.8 | 140.0 | 265.1 |
| Wheat bran | - | - | - | - | 86.5 | 240.0 | - |
| UNIMIX | 400.0 | 50.0 | 20.0 | 20.0 | 25.0 | 25.0 | 30.0 |
| L-lysine | - | - | - | - | - | - | 10.0 |
| DL-methionine | - | - | - | - | - | - | 2.0 |
| Sugar | - | - | - | - | - | - | 100.0 |
| Calcitic limestone | - | - | - | - | 2.3 | - | 4.1 |
| Mycofix | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
|
| |||||||
| Dry matter, % | 83.41 | 87.92 | 87.07 | 88.93 | 88.12 | 89.42 | 88.25 |
| Ashes, % | 6.69 | 5.43 | 4.80 | 3.70 | 4.54 | 5.23 | 5.62 |
| Crude energy, cal.g-1 | 4347.0 | 4393.0 | 4419.0 | 4465.0 | 4411.5 | 4360.0 | 4376.0 |
| Ether extract, % | 4.14 | 1.71 | 2.41 | 1.71 | 1.37 | 1.40 | 1.56 |
| Crude fiber, % | 4.54 | 4.32 | 4.30 | 4.07 | 3.01 | 5.23 | 5.28 |
| Crude protein, % | 18.04 | 21.21 | 18.07 | 20.46 | 19.04 | 17.59 | 19.99 |
| Calcium, % | 0.90 | 0.80 | 0.63 | 0.51 | 0.82 | 0.81 | 0.94 |
| Phosphorus, % | 0.69 | 0.53 | 0.41 | 0.37 | 0.38 | 0.46 | 0.43 |
aThe premix used in each phase was based on Rostagno et al. [18].
The lipid fraction of enriched cow’s milk.
| Fatty acid profile | Treatments | P-value | ||||
|---|---|---|---|---|---|---|
| Control | n-3 | n-6 | Treatment | C1 | C2 | |
| ΣSFA | 66.887 ± 1.40 | 56.605 ± 1.40 | 56.524 ± 1.40 |
|
| 0.969 |
| ΣUSFA | 33.051 ± 1.40 | 43.346 ± 1.40 | 43.394 ± 1.40 |
|
| 0.986 |
| SFA/USFA | 2.121 ± 0.10 | 1.364 ± 0.10 | 1.341 ± 0.10 |
|
|
|
| ΣMUFA | 29.583 ± 1.30 | 39.470 ± 1.30 | 39.551 ± 1.30 |
|
| 0.966 |
| ΣPUFA | 3.570 ± 0.30 | 3.979 ± 0.30 | 3.935 ± 0.20 | 0.199 | 0.076 | 0.860 |
| Σn-3 | 0.324 ± 0.03 | 1.022 ± 0.03 | 0.360 ± 0.03 |
|
|
|
| Σn-6 | 2.483 ± 0.20 | 2.252 ± 0.20 | 2.880 ± 0.20 |
| 0.589 |
|
| n-6/n-3 | 7.919 ± 0.50 | 2.724 ± 0.50 | 8.263 ± 0.50 |
|
|
|
| Cholesterol, g.100 mL-1 | 9.942 ± 1.60 | 8.741 ± 1.60 | 10.053 ± 1.70 | 0.174 | 0.403 | 0.097 |
aΣSFA = Σ saturated fatty acids; ΣUSFA = Σ unsaturated fatty acids; SFA/USFA = Σ saturated/Σ unsaturated; ΣMUFA = Σ monounsaturated fatty acids; ΣPUFA = Σ polyunsaturated fatty acids; Σ n-3 = Σ omega-3 fatty acids; Σ n-6 = Σ omega-6 fatty acids; n-6/ n-3 = Σ omega-6/Σ omega-3.
bCows fed with a unsupplemented oil diet (Control); supplemented with linseed oil (n-3); or soybean oil (n-6).
cC1, contrast between Control vs. n-3+n-6; C2 = contrast between n-3 vs. n-6.
Effect of supplementation of milk enriched with n-3 and n-6 on growth performance and feed efficiency of gilts from 34 to 190 days of age.
| Treatments | P-value | |||||||
|---|---|---|---|---|---|---|---|---|
| Item | Control | n-3 | n-6 | Treatment | Time | Treat*Time | C1d | C2d |
| BW, kg | 67.570 ± 2.60 | 67.540 ± 2.60 | 66.750 ± 2.70 | 0.942 |
| 0.929 | 0.947 | 0.915 |
| ADG, kg.dia-1 | 0.754 ± 0.04 | 0.750 ± 0.04 | 0.734 ± 0.04 | 0.864 |
| 0.967 | 0.760 | 0.729 |
| ADFI, kg.dia-1 | 2.348 ± 0.04 | 2.356 ± 0.04 | 2.328 ± 0.05 | 0.846 |
| 0.949 | 0.951 | 0.812 |
| FC ratio, kg.kg-1 | 3.138 ± 0.04 | 3.147 ± 0.06 | 2.990 ± 0.06 | 0.870 |
| 0.948 | 0.598 | 0.323 |
aBW: Body weight; ADG: Average daily gain; ADFI: Average daily feed intake; FC ratio: Feed:gain ratio.
bGilts fed with non-enriched milk (Control); or supplemented with cow’s milk enriched with n-3 or n-6.
cC1, contrast between Control vs n-3+n-6; C2, contrast between n-3 vs n-6.
Fig 1Tendency to increase myristic acid for Control treatment at 77 days of age of gilts.
Fig 2γ-linolenic tends to have a higher concentration in n-3 treatment at 132 days of age of gilts.
Effect of supplementation of milk enriched with n-3 and n-6 on serum fatty acids profile of gilts from 34 to 190 days of age.
| Fatty acids | Treatments | P-value | ||||||
|---|---|---|---|---|---|---|---|---|
| Control | n-3 | n-6 | Treatment | Time | Treat*Time | C1d | C2d | |
| Myristic, C14:0 | 0.869 ± 0.070 | 0.669 ± 0.070 | 0.653 ± 0.070 | 0.087 |
| 0.062 |
| 0.875 |
| Palmitic, C16:0 | 17.730 ± 0.700 | 17.800 ± 0.700 | 17.490 ± 0.070 | 0.950 |
| 0.541 | 0.925 | 0.766 |
| Stearic, C18:0 | 12.430 ± 0.300 | 11.830 ± 0.300 | 13.560 ± 0.300 | 0.006 |
| 0.408 | 0.497 |
|
| Elaidic, C18:1t n-9 | 0.382 ± 0.080 | 0.293 ± 0.080 | 0.379 ± 0.080 | 0.686 |
| 0.174 | 0.652 | 0.470 |
| Palmitoleic, C16:1c9 | 1.136 ± 0.090 | 1.167 ± 0.100 | 1.117 ± 0.090 | 0.936 |
| 0.937 | 0.961 | 0.721 |
| Oleic, C18:1c9 | 23.330 ± 0.700 | 24.050 ± 0.700 | 22.130 ± 0.700 | 0.200 |
| 0.684 | 0.790 | 0.081 |
| Linoleic, C18:2 n-6 | 28.390 ± 0.500 | 29.770 ± 0.500 | 28.670 ± 0.600 | 0.225 |
| 0.708 | 0.242 | 0.190 |
| Dihomo-γ-linolenic, C20:3 n-6 | 0.695 ± 0.0400 | 0.688 ± 0.040 | 0.660 ± 0.050 | 0.852 |
| 0.637 | 0.714 | 0.679 |
| ARA, C20:4 n-6 | 11.240 ± 0.500 | 11.000 ± 0.600 | 12.410 ± 0.600 | 0.239 |
| 0.587 | 0.534 | 0.121 |
| γ-Linolenic, C18:3 n-6 | 0.506 ± 0.020 | 0.567 ± 0.030 | 0.531 ± 0.030 | 0.336 |
| 0.079 | 0.232 | 0.381 |
| α-Linolenic, C18:3 n-3 | 0.563 ± 0.020 | 0.618 ± 0.030 | 0.588 ± 0.020 | 0.361 |
| 0.326 | 0.232 | 0.431 |
| EPA, C20:5 n-3 | 0.219 ± 0.090 | 0.343 ± 0.090 | 0.461 ± 0.100 | 0.239 | 0.1157 | 0.280 | 0.143 | 0.397 |
| DHA, C22:6 n-3 | 1.203 ± 0.100 | 1.184 ± 0.100 | 1.371 ± 0.100 | 0.459 |
| 0.300 | 0.617 | 0.260 |
| Saturated | 31.410 ± 0.300 | 30.370 ± 0.300 | 31.150 ± 0.300 | 0.090 |
| 0.450 | 0.124 | 0.106 |
| Unsaturated | 68.590 ± 0.300 | 69.630 ± 0.300 | 68.850 ± 0.300 | 0.090 |
| 0.450 | 0.124 | 0.106 |
| SFA/USFA | 0.458 ± 0.006 | 0.438 ± 0.006 | 0.453 ± 0.006 | 0.097 |
| 0.472 | 0.132 | 0.110 |
| Monounsaturated | 25.240 ± 0.600 | 25.430 ± 0.700 | 24.040 ± 0.600 | 0.312 |
| 0.234 | 0.547 | 0.164 |
| Polyunsaturated | 43.340 ± 0.800 | 44.200 ± 0.800 | 44.880 ± 0.800 | 0.438 | 0.2194 | 0.229 | 0.255 | 0.563 |
| Total n-3 | 2.002 ± 0.100 | 2.154 ± 0.100 | 2.384 ± 0.100 | 0.197 |
| 0.296 | 0.152 | 0.262 |
| Total n-6 | 41.350 ± 0.700 | 42.050 ± 0.700 | 42.480 ± 0.800 | 0.596 |
| 0.458 | 0.354 | 0.694 |
| n-6/n-3 | 27.271 ± 1.100 | 26.347 ± 1.100 | 25.528 ± 1.100 | 0.559 |
| 0.459 | 0.341 | 0.612 |
| ARA/EPA | 59.854 ± 6.800 | 57.438 ± 6.800 | 46.762 ± 6.800 | 0.379 |
| 0.174 | 0.368 | 0.285 |
aEPA: Eicosapentaenoic acid; DHA: Docosahexaenoic acid; ARA: Arachidonic acid; USFA/SFA: Unsaturated/saturated fatty acids; Total n-3: Sum of n-3 fatty acids; Total n-6: Sum of n-6 fatty acids; n-6/n-3, ratio of total n-6 to total n-3 fatty acids; ARA/EPA: Ratio of arachidonic acid to eicosapentaenoic acid.
bGilts fed with non-enriched milk (Control); or supplemented with cow’s milk enriched with n-3 or n-6.
cC1, contrast between Control vs n-3+n-6; C2, contrast between n-3 vs n-6.
Fig 3Behavior of the LDL curve at 77 days of gilts.
Effect of supplementation of milk enriched with n-3 and n-6 on serum biochemical parameters of gilts from 34 to 190 days of age.
| Biochemical parameters | Treatments | P-value | ||||||
|---|---|---|---|---|---|---|---|---|
| Control | n-3 | n-6 | Treatment | Time | Treat*Time | C1c | C2c | |
| Urea, mg.dL-1 | 23.590 ±1.00 | 24.370 ± 1.00 | 24.380 ± 1.00 | 0.833 |
| 0.851 | 0.722 | 0.978 |
| Total protein, g.dL-1 | 5.760 ± 0.07 | 5.720 ± 0.07 | 5.810 ± 0.07 | 0.661 |
| 0.332 | 0.959 | 0.634 |
| Total cholesterol, mg.dL-1 | 79.180 ± 2.20 | 77.110 ± 2.20 | 79.350 ± 2.30 | 0.747 |
| 0.181 | 0.687 | 0.490 |
| Glucose, mg.dL-1 | 90.330 ± 1.60 | 85.510 ± 1.60 | 86.490 ± 1.60 | 0.101 |
| 0.198 | 0.133 | 0.768 |
| Triglycerides, mg.dL-1 | 35.890 ± 2.90 | 37.300 ± 2.90 | 32.490 ± 2.80 | 0.501 |
| 0.517 | 0.751 | 0.275 |
| HDL, mg.dL-1 | 25.990 ± 1.00 | 25.050 ± 1.00 | 28.020 ± 1.00 | 0.145 |
| 0.812 | 0.730 | 0.063 |
| LDL, mg.dL-1 | 46.020 ± 1.50 | 44.510 ± 1.50 | 44.910 ± 1.60 | 0.773 |
| 0.083 | 0.540 | 0.861 |
| VLDL, mg.dL-1 | 7.200 ± 0.50 | 7.520 ± 0.50 | 6.690 ± 0.60 | 0.595 |
| 0.782 | 0.857 | 0.337 |
aGilts fed with non-enriched milk (Control); or supplemented with cow’s milk enriched with n-3 or n-6.
bC1, contrast between Control vs n-3+n-6; C2, contrast between n-3 vs n-6.
Effect of supplementation of milk enriched with n-3 and n-6 on hemogram and leukogram of gilts from 34 to 190 days of age.
| Item | Treatments | P-value | ||||||
|---|---|---|---|---|---|---|---|---|
| Control | n-3 | n-6 | Treatment | Time | Treat*Time | C1d | C2d | |
| Hemogram | ||||||||
| RBC, 106. mm-3 | 7.188 ± 0.1 | 7.465 ± 0.1 | 7.484 ± 0.1 | 0.149 |
| 0.127 | 0.053 | 0.908 |
| Hemoglobin, g.dl-1 | 12.248 ± 0.1 | 12.298 ± 0.1 | 12.297 ± 0.1 | 0.963 |
| 0.163 | 0.786 | 0.999 |
| Hematocrit, % | 40.182 ± 0.6 | 40.423 ± 0.6 | 40.808 ± 0.6 | 0.750 |
| 0.111 | 0.543 | 0.642 |
| MCV, fl | 55.984 ± 0.8 | 54.222 ± 0.8 | 54.602 ± 0.8 | 0.283 | 0.6070 | 0.366 | 0.125 | 0.748 |
| MCH, pg | 17.045 ± 0.2 | 16.472 ± 0.3 | 16.448 ± 0.2 | 0.188 |
| 0.622 | 0.070 | 0.948 |
| MCHC, % | 30.484 ± 0.2 | 30.416 ± 0.2 | 30.126 ± 0.1 | 0.246 |
| 0.313 | 0.264 | 0.198 |
| Platelets, x105.mm-3 | 2.673 ± 0.2 | 3.202 ± 0.2 | 3.028 ± 0.2 | 0.140 |
| 0.674 | 0.064 | 0.521 |
| Leukogram | ||||||||
| Leukocytes, x103.mm-3 | 12.78 ± 0.6 | 14.20 ± 0.6 | 14.47 ± 0.7 | 0.137 |
| 0.918 |
| 0.766 |
| Segmented, x103.mm-3 | 5.11 ± 1.1 | 5.62 ± 1.1 | 4.96 ± 1.1 | 0.302 |
| 0.972 | 0.665 | 0.147 |
| Lymphocytes, x103.mm-3 | 6.33 ± 1.0 | 7.07 ± 1.1 | 7.91 ± 1.1 | 0.139 |
| 0.732 | 0.089 | 0.294 |
| Monocytes, x103.mm-3 | 1.07 ± 0.1 | 0.80 ± 0.1 | 0.84 ± 0.1 | 0.517 |
| 0.736 | 0.257 | 0.890 |
| Eosinophils, x103.mm-3 | 0.32 ± 0.1 | 0.23 ± 0.1 | 0.33 ± 0.1 | 0.488 |
| 0.918 | 0.553 | 0.281 |
aRBCs: Red blood cells; MCV: Mean corpuscular volume; MCH: Mean corpuscular hemoglobin; MCHC: Mean corpuscular haemoglobin concentration.
bGilts fed with a non-enriched milk (Control); or supplemented with cow’s milk enriched with n-3 or n-6.
cC1, contrast between Control vs n-3+n-6; C2, contrast between n-3 vs n-6.